Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 2/20 | 0.36 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.36 |
| ▸ | CPT1A | P50416 | 1/20 | 0.34 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | USP36 | Q9P275 | 1/20 | 0.32 |
| ▸ | IDH1 | O75874 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 5/20 | 0.32 |
| ▸ | GLS | O94925 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
| ▸ | DHODH | Q02127 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10090026 | 0.95 | PPARG (0.38) | PPARGNR1I2CPT1ACPT1BMAPT | |
| SCHEMBL10089916 | 0.95 | KCNB1 (0.36) | PPARGMMP13CNR2 | |
| SCHEMBL10089960 | 0.93 | MMP13 (0.38) | MAPTLMNAPOLBMMP13DHODH | |
| SCHEMBL10089975 | 0.93 | SLC2A1 (0.35) | PPARGNR1I2CPT1ACPT1BIDH1 | |
| SCHEMBL10089898 | 0.93 | PDE2A (0.35) | PPARGLMNAALDH1A1 | |
| SCHEMBL10089892 | 0.92 | DHODH (0.38) | PPARGPOLBIDH1MMP13DHODH | |
| SCHEMBL10089909 | 0.92 | PPARG (0.36) | PPARGNR1I2CPT1ACPT1BLMNA | |
| SCHEMBL10089874 | 0.91 | MMP13 (0.36) | PPARGMAPTLMNAIDH1MMP13 | |
| SCHEMBL10089858 | 0.91 | IDH1 (0.40) | PPARGIDH1ELANEMMP13DHODH | |
| SCHEMBL10089967 | 0.91 | DHODH (0.36) | PPARGLMNAIDH1MMP13DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791143-B2 | Anthranilic diamide derivatives having cyclic side-chains | BAYER CROPSCIENCE AG (DE) | 2014-07-29 | — | — | US | disclosed |
| US-20120010249-A1 | Anthranilic diamide derivatives having cyclic side-chains | BAYER CROPSCIENCE AG (DE) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010249-A1 | Anthranilic diamide derivatives having cyclic side-chains | DDT, ADCY1, ANTXR2 | PPARG 3227/4885NR1I2 2630/4885CPT1A 3152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.